Pfizer probably did more than any other company to help the world normalize from the pandemic, and it reaped a financial windfall from its twin Covid-19 franchise—the top-selling vaccine and the leading treatment, Paxlovid.
The world, however, has stopped worrying about Covid—and Pfizer (ticker: PFE) is paying the price. The sales of its two Covid blockbusters may decline over 60% in 2023, after generating a combined $57 billion in revenue during 2022. And there is considerable uncertainty about demand for both in the coming years.
Source: finance.yahoo.com
Related posts:
Congress deliberates a $52 billion semiconductor bill — Here are 2 stocks that could benefit
A tech founder who didn’t pay employees for months but bought a $16 million private jet has been arr...
JPMorgan, Other Banks in Talks to Reimburse Scammed Zelle Customers
Banks Lose Billions in Value After Tech Lender SVB Stumbles
3 Reasons to Buy Nvidia After Its Stock Split and 1 Reason to Sell